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Since there are no published data on breast cancer in British black women, we sought to determine whether, like African-American
women, they present at a younger age with biologically distinct disease patterns. The method involved a retrospective review of
breast cancer to compare age distributions and clinicopathological features between black women and white women in the UK, while
controlling for socioeconomic status. All women presented with invasive breast cancer, between 1994 and 2005, to a single East
London hospital. Black patients presented significantly younger (median age of 46 years), than white patients (median age of 67 years
(P¼0.001)). No significant differences between black and white population structures were identified. Black women had a higher
frequency of grade 3 tumours, lymph node-positive disease, negative oestrogen receptor and progesterone receptor status and
basal-like (triple negative status) tumours. There were no differences in stage at presentation; however, for tumours of p2cm, black
patients had poorer survival than white patients (HR¼2.90, 95% CI 0.98–8.60, P¼0.05). Black women presented, on average, 21
years younger than white women. Tumours in younger women were considerably more aggressive in the black population, more
likely to be basal-like, and among women with smaller tumours, black women were more than twice as likely to die of their disease.
There were no disparities in socioeconomic status or treatment received. Our findings could have major implications for the biology
of breast cancer and the detection and treatment of the disease in black women.
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While the incidence of breast cancer in women of African descent
is lower than that of their white counterparts, paradoxically, the
age adjusted breast cancer rates are higher (Elledge et al, 1994;
Brawley, 2002). Black women have been shown to present with a
more advanced stage of disease and at a younger age in published
American and African studies (Adebamowo and Adekunle, 1999;
Joslyn and West, 2000). There are, however, no published data on
breast cancer presentation in the British black population.
From the American studies it appears that up to 35% of black
breast cancer patients are under 50 years old, compared with only
20% of white women with breast cancer (Elledge et al, 1994;
Newman and Alfonso, 1997; El-Tamer et al, 1999). African-
American (A-A) women had significantly larger tumours, lower
rates of localised disease and higher rates of oestrogen receptor
(ER) and progesterone receptor (PgR) negativity, all of which
confer a poorer prognosis (Elledge et al, 1994; Joslyn and West,
2000; Newman et al, 2002; Jones et al, 2004; Gukas et al, 2005).
These A-A women were more likely than white patients to present
with poorly differentiated and medullary-like tumours, and they
might have up to double the incidence of inflammatory carcinoma,
the most aggressive form of breast cancer (Chang et al, 1998;
Joslyn and West, 2000; Newman et al, 2002). Recent studies,
analysing molecular subtypes, suggest there is a higher frequency
of the poor-prognosis basal subgroup (frequently referred to as
triple negative) in young black American women (Carey et al,
2006).
Critics of the A-A data dispute the contributory impact of
factors such as socioeconomic differences (Eley et al, 1994) and
disparities in access to, and receipt of, health care between the
ethnic groups (Dignam et al, 1997; Bickell et al, 2006). Although
any such variations are more likely to contribute to outcome rather
than age at presentation, the differences in health care systems
between the USA and the UK have made it possible for us to
control for these factors in a way that has not been possible in
previously published studies.
Until now there have been no data on the patterns of
breast cancer in British black women. Similarities with the A-A
population have been assumed by most UK doctors, but this
may well be an unwarranted assumption. It would seem prudent
to review the biology of the disease in this group because of
the potentially different genetic backgrounds between A-A and
British black women. For example, use of population-specific
alleles has shown European admixture to be considerably higher
in African-Americans than in their Jamaican counterparts
(Parra et al, 1998), and Afro-Caribbean people make up a
substantial proportion of the British black population. Whether
or not the British black population have a higher frequency
of basal tumours, or if they have distinct molecular characteristics,
certainly has never been addressed, although this could have
major implications for breast cancer care in the UK, including
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sscreening and treatment protocols. Because ethnicity often has
not been noted in many Registry databases, we have conducted a
pilot study on a single hospital where up to 25% of the local
referral population is black. Supposing our results can be
extrapolated to the general black population in the UK, our
findings could have implications for both the detection and
treatment of breast cancer in this group of women. In more general
terms, the differences we have detected between breast cancer in
this group of British black women and the disease as reported in
A-A women have significance for our understanding of its
underlying biology.
MATERIALS AND METHODS
Women presenting at the Homerton University Hospital in
Hackney, East London, between 1994 and 2005, with a diagnosis
of invasive breast cancer, were entered into a database following
local ethics approval. Where possible, details of age at presenta-
tion, self-reported ethnicity, grade, lymph node status, stage, ER,
PgR and ERBB2 (v-erb-b2 erythroblastic leukaemia viral oncogene
homologue 2) status were recorded. From 2001 onward the
hospital routinely recorded all incident breast cancers in the BASO
database (British Association of Surgical Oncologists) and this
is used currently in clinical practice. No such routine centralized
data collection existed before 2001 and therefore the hospital
computerized discharge summaries between 1994 and 2000 were
searched. Histological diagnosis was confirmed by review of
histology reports. Where ethnicity was undisclosed or histological
diagnosis unconfirmed, patients were excluded. Only invasive
breast cancer was included. The tumour specimens for each
patient were retrieved from pathology archives and stained for ER,
PgR and ERBB2 by immunohistochemistry (IHC) where this
information was otherwise missing. Socioeconomic status was
measured using the Index of Multiple Deprivation (IMD), a proxy
for socioeconomic status, as determined by area of residence
(Jordan et al, 2004). The IMD uses six domains to assess a given
ward: income, employment, health deprivation and disability,
education skills and training, housing and geographical access to
services. Hackney was reported to be the most deprived area of
London by IMD 2004.
For comparative purposes the details of all black patients
presenting to the same hospital with cancer of any type during
2000–2007 were also recorded.
Statistical methods
Age distributions of the black patients and white patients were
compared using Poisson regression, adjusting for the different age
distributions of the entire local populations. This was accom-
plished using the 2001 census figures for Hackney, London, where
the majority of the patients resided (http://www.statistics.gov.uk/
census, 2001). These were available only in three broad age groups,
0–15, 16–59 and 60 or more. Histological and biological features
of the tumours were compared using logistic regression, adjusting
for age in the first instance, and then for age and IMD. Survival
analysis was by proportional hazards regression, also adjusting
for age and IMD (Cox, 1972). We also tested for heterogeneity of
results by tumour size and age, usually dichotomising age at a
cut-off of 60 years, as this was the approximate median age in the
two groups combined.
RESULTS
A total of 445 patients with a new diagnosis of breast cancer made
between 1994 and 2005 were identified. Nine white women and one
black woman were removed from the cohort because histological
review revealed a diagnosis of only ductal carcinoma in situ
(DCIS). Sixteen white women were excluded because their initial
diagnosis proved to have been before 1994. There were 126 women
from other ethnic groups (5 Greek, 35 Jewish, 9 Turkish, 2
Chinese/Vietnamese, 3 Arabic and 19 Indian women), or where
ethnicity was undisclosed, who were excluded from the cohort
analysis. Data were obtained from 102 black women and 191 white
British women.
The distributions of age at diagnosis in the black cohort and
white cohort are demonstrated in Figure 1. This shows that the
black patients were significantly younger (P¼0.001), with a
median age of 46 compared with 67 for the white patients. To
address whether this difference in the age at presentation simply
reflected differences in the age structure of the two ethnic
populations locally, the patient cohorts were compared with the
population census data of Hackney (Table 1). No significant
difference between the black and the white population structures
was identified, confirming that there is a true increase in the
frequency of breast cancer in young black women. Moreover, no
other common cancer in the same population of black women
revealed a comparable increase in frequency in younger women
(data not shown).
The pathological and biological features of the tumours in the
two patient cohorts were compared (Table 2). Total numbers vary
due to differing numbers of cases with missing data for each
variable; however, black patients had a greater frequency of grade
3 tumours, lymph node-positive disease and negative ER and
PgR status, compared with white women. They also had higher
proportions of tumours of basal or triple negative status (as
defined here by ER-negative, PgR-negative and ERBB2-negative
status). The difference reached statistical significance only for
histological grade (P¼0.02). Results were unchanged when further
adjusted for IMD.
There was borderline significant heterogeneity by age of the
association of ethnicity with ER status (P¼0.05) such that in
patients aged under 60, the black patients were significantly more
likely to have ER-negative disease (OR¼2.36, 95% CI 1.06–5.00,
P¼0.03), but there was no significant difference in ER status by
ethnicity in patients aged 60 years or above (OR¼0.71, 95% CI
0.23–2.18, P¼0.5). A similar heterogeneity of borderline sig-
nificance was noted for basal status (P¼0.09). In women aged
under 60 years, black patients were more likely to have triple
negative disease (OR¼2.33, 95% CI 0.88–6.18), whereas in women
Age distribution of women presenting with breast cancer
between 1994 and 2005
0
10
20
30
40
0–20 21–30 31–40 41–50 51–60 61–70 71–80 81–90 91–100
Age
%
White women Black women
Figure 1 Age distribution of women presenting with breast cancer
between 1994 and 2005.
Table 1 Age distribution of 293 breast cancer patients, and of the
Hackney population, by ethnic group
Black White
Age group
Patients
(%)
Population
(%)
Patients
(%)
Population
(%)
16–59 75 (74) 16600 (86) 64 (34) 41600 (80)
60+ 27 (26) 2600 (14) 127 (66) 10300 (20)
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saged 60 or more, there were no significant or suggestive differences
between the two ethnic groups (OR¼0.67, 95% CI 0.13–3.39). The
ER and triple negative status by age group and ethnicity is shown
in Table 3.
For overall survival analysis, there was an average follow-up of 3
years and a maximum of 12 years. The number of patient deaths by
age group and ethnicity is shown in Table 4. Adjusting for age and
IMD, no significant difference in survival was detected between
black patients and white patients (HR¼0.98, 95% CI 0.61–1.55,
P¼0.9). There was, however, significant heterogeneity of the effect
of ethnic group in tumours of different sizes (P¼0.002). In
tumours of size 2cm or less, black patients had poorer survival
than white patients (HR¼2.90, 95% CI 0.98–8.60, P¼0.05),
although for tumours greater than 2cm, there was no significant or
substantial difference in survival (HR¼0.86, 95% CI 0.44–1.65,
P¼0.6) (Figure 2). The result was not changed substantially when
further adjusted for grade and ER status. Survival by ethnicity for
average age (61 years) and IMD score (46), in tumours of size 2cm
or less from the Cox regression, is shown in Figure 2.
DISCUSSION
This study has demonstrated a substantial difference in age at
presentation for breast cancer between white women and black
women living in a geographically restricted deprived area of
London. Black women presented on average 21 years younger than
their white counterparts (a median age of 46 years), and this is
earlier than the current threshold age of 50 years for entry to the UK
National Health Service Breast Screening Programme (NHS BSP).
By selecting a single district hospital, the patients in this pilot
study come from a limited geographical referral area, which
controls, to a large extent, for the socioeconomic differences
associated with risk of disease, accessibility to health resources and
Table 2 Pathological and biological tumour features in black and white
breast cancer patients
Factor Category
Black patient
no. (%)
White patient
no. (%) Significance
a
Tumour size p2cm 39 (41) 64 (45) 0.2
42cm 55 (59) 77 (55)
Total 94 (100) 141
Node status Negative 34 (35) 58 (41) 0.2
Positive 62 (65) 85 (59)
Total 96 (100) 143 (100)
Histological grade 1 6 (6) 18 (12) 0.02
2 30 (32) 66 (46)
3 57 (62) 60 (42)
Total 93 (100) 144 (100)
Oestrogen
receptor status
Negative 32 (34) 34 (25) 0.2
Positive 61 (66) 102 (75)
Total 93 (100) 136 (100)
Progesterone
receptor status
Negative 32 (36) 34 (25) 0.5
Positive 58 (64) 102 (75)
Total 90 (100) 136 (100)
Her2/neu status Negative 56 (66) 83 (65) 0.6
Positive 29 (34) 44 (35)
Total 85 (100) 127 (100)
Triple negative
status
Negative 63 (78) 99 (85) 0.2
Positive 18 (22) 17 (15)
Total 81 (100) 116 (100)
aAdjusted for age.
Table 3 ER status and triple negative status by age and ethnicity
Factor Age group Category Black patient no. (%) White patient no. (%) Significance
ER status o60 Negative 27 (39) 13 (21) 0.03
Positive 43 (61) 48 (79)
Total 70 (100) 61 (100)
60+ Negative 5 (22) 21 (28) 0.5
Positive 18 (78) 54 (72)
Total 23 (100) 75 (100)
Triple negative status o60 Negative 48 (75) 49 (88) 0.09
Positive 16 (25) 7 (12)
Total 64 (100) 56 (100)
60+ Negative 15 (88) 50 (83) 0.6
Positive 2 (12) 10 (17)
Total 17 (100) 60 (100)
ER¼oestrogen receptor.
Table 4 Patients and deaths by age and ethnicity
Ethnicity Age group Patients Deaths (% of patients)
Black patients o40 19 5 (26)
40–49 38 8 (21)
50–59 18 10 (56)
60–69 14 6 (42)
70+ 13 5 (38)
White patients o40 8 2 (25)
40–49 32 5 (16)
50–59 24 7 (29)
60–69 39 17 (44)
70+ 88 61 (69)
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Figure 2 Age and IMD-adjusted estimated survival by ethnic group, for
tumours of size 2cm or less.
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sinequalities in receipt of treatment which might have accounted
for these differences. This was further controlled for by generating
an IMD score for each patient and adjusting for this in the analysis.
This approach has restricted the number of cases that can be
included in the study, but it has meant that the results are not a
consequence of these variables.
Information on age of incidence of invasive breast cancer cases
in London between 1994 and 2004 (41792 women inclusive of all
ethnic origins) is available. Twenty-five percent of all breast cancer
cases in London presented at 45 years or younger compared with
45% of black women with breast cancer in our local population. It
is crucial, therefore, to target this group of women to raise their
awareness regarding the risks of breast cancer, the likelihood of
early age at presentation and the importance of self-examination
and early presentation with clinical signs.
The UK NHS BSP is offered to all women between 50 and 70
years, with an invitation to mammography on a 3 yearly basis.
Alterations to the screening services offered to black populations
might be considered to better reflect the incidence patterns for this
group, much as it has been for those individuals with a family
history deemed to be at risk of breast cancer at a younger age.
Additional resources required for the screening of black women
from age 40 or 45 would be modest, but there could be
organizational difficulties in identifying the relevant population
for invitation.
There has been much speculation regarding biological factors,
which may underpin ethnic differences in breast cancer biology,
presentation and outcome (Elledge et al, 1994; Joslyn and West,
2000). In our cohort, 62% of black women had grade 3 tumours
compared with 42% of white women. Women under 50 years tend
to have an increased rate of higher grade tumours. However, even
after adjusting for age, there were significantly more grade 3
tumours in black women. Thus, it is not simply a consequence of
the higher representation of younger women in the black cohort.
Also, among those women with smaller tumours (p2cm), black
women were more than twice as likely to die of their disease
(P¼0.05). Review of the database has shown that black women
received more adjuvant therapy (chemotherapy, radiotherapy and,
where appropriate, hormone therapy) than their white counter-
parts. Thus, there is no evidence that observed differences are due
to late presentation or inequalities in the receipt of therapy and,
therefore, breast cancers arising in young black women appear to
be biologically different; an effect not attributable simply to the
young age of affected individuals.
It also is worth noting a particularly novel finding of our study
that is, not only do British black women develop breast cancer at a
younger age, but also smaller tumours (p2cm) in young women
show very different behaviour between the two ethnic groups.
Tumours in younger women are considerably more aggressive
in black women. Breast tumours in women over 60 years show
similar behaviour regardless of ethnic origin. That the lymph node
status and stage at presentation were similar between both ethnic
groups also differs from reported findings in the A-A populations
(Elledge et al, 1994; Newman et al, 2002).
Factors such as obesity, family history, low parity, later age at
first full-term pregnancy, not breast feeding and long duration
of reproductive period all are known to increase the risk of
developing breast cancer (Collaborative Group on Hormonal
Factors in Breast Cancer, 2002) and may differ significantly
between ethnic groups. These risk factors have been associated
with breast cancer in African women (Okobia et al, 2006) and may
contribute to our observed differences to some extent.
Much of the work done in this area has attempted to try to
explain the variation in outcome between A-A women and age-
and stage-matched white Caucasians. Differences in receipt of
optimal treatment have been cited as a possible cause (Dignam
et al, 1997; Hershman et al, 2005). However, a pooled analysis of
women treated within clinical trials, thus controlling for disease
stage and receipt of treatment, still found significant differences in
outcome for both pre- and post-menopausal A-A women (Albain
et al, 2003). Such data suggest that biological features of the
tumours are, at least partly, responsible for these ethnic differences
(Selaru et al, 2004; Newman et al, 2006). Disease pattern variation
between the ethnic groups is not explained by overexpression of
the oncogene cerbB2þ, as this does not differ significantly across
racial groups (Carey et al, 2006).
Recent gene expression analyses of breast cancers have
confirmed the existence of distinct molecular subgroups (Perou
et al, 2000; Sorlie et al, 2003; Carey et al, 2006). There has been
particular interest in the subgroup of basal-like tumours,
which express many myoepithelium-associated genes, such as
cytokeratin 5, and which are both cerbB2- and ER-negative and are
associated with a poor prognosis (Turner et al, 2005). The basal
phenotype is more common in breast cancers arising in young
women and in BRCA-1-mutated cancers, to which patterns of
disease in black women bear many similarities (Newman et al,
2002; Sorlie et al, 2003). Of note, A-A women do not appear to have
a greater prevalence of high-risk BRCA mutations than the white
Caucasian population (Frank et al, 2002; Olopade et al, 2003;
Nanda et al, 2005), but the basal-like subtype is known to be more
prevalent among young (premenopausal) A-A women with breast
cancer (Carey et al, 2006). We noted it to be more prevalent, based
on immunohistochemical analysis, in the British black population
(22%), albeit at a much lower level than in the A-A population
(39%). However, it also is apparent that the basal subtype is a
heterogeneous group (Vincent-Salomon et al, 2007), and further
analysis is required to more accurately define the precise nature of
the tumours in these women. A detailed analysis of these tumours,
using a more extensive panel of IHC markers to delineate the basal
phenotype, is warranted. Of note, basal and ERBB2 subgroups have
been found to respond better to 5-fluorouarcil, doxorubicin and
cyclophosphamide chemotherapy relative to other breast cancer
subgroups (Rouzier et al, 2005). Studies have shown that most
triple negative tumours are included within this basal subset
(Perou et al, 2000; Sorlie et al, 2001, 2003; van’t Veer et al, 2002).
These triple negative breast cancers are resistant to existing
targeted treatments, such as hormonal treatments and trastuzumab,
underscoring the clinical importance of defining new potential
targets for treatment in this group. Interestingly, due to the
characteristic defects in DNA repair seen in BRCA1 mutation-
associated tumours, sensitivities to standard cytotoxic agents differ
compared with other breast cancers (Bhattacharyya et al, 2000;
Quinn et al, 2003). Novel targeted agents, being investigated in
BRCA1/triple negative tumours, may also be of benefit in black
women.
When specific gene expression signatures are anticipated to
revolutionise the diagnosis and treatment of cancer, it may be
important to recognise the distinct biological characteristics
occurring within specific ethnic populations, and also the subtle
differences between apparently similar populations, such as the
A-A and British black populations, which might impact on these
profiles.
In summary, we have shown that British black women, as
often assumed by many UK clinicians, do share certain
characteristics with their A-A counterparts with regard to breast
cancer. There are although certain differences between these two
groups, as exemplified by the aggressive behaviour of small
tumours, which indicate that the two cohorts cannot be considered
identical.
ACKNOWLEDGEMENTS
This research was supported by: The Gordon Hamilton Fairley
Fellowship, Cancer Research UK and Barts and The London
Charitable Foundation.
Breast cancer patterns in British black women
RL Bowen et al
280
British Journal of Cancer (2008) 98(2), 277–281 & 2008 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sREFERENCES
Adebamowo CA, Adekunle OO (1999) Case–controlled study of the
epidemiological risk factors for breast cancer in Nigeria. Br J Surg 86:
665–668
Albain K, Unger JM, Hutchins LF, Rivkin SE, Martino S, Livingston RB,
Osborne CK (2003) Outcome of African Americans on Southwest
Oncology Group (SWOG) Breast Cancer Adjuvant Therapy Trials (abstr
21) San Antonio Breast Cancer Symposium. San Antonio, TX
Bhattacharyya A, Ear US, Koller BH, Weichselbaum RR, Bishop DK (2000)
The breast cancer susceptibility gene BRCA1 is required for subnuclear
assembly of Rad51 and survival following treatment with the DNA cross-
linking agent cisplatin. J Biol Chem 275: 23899–23903
Bickell NA, Wang JJ, Oluwole S, Schrag D, Godfrey H, Hiotis K, Mendez J,
Guth AA (2006) Missed opportunities: racial disparities in adjuvant
breast cancer treatment. J Clin Oncol 24: 1357–1362
Brawley OW (2002) Disaggregating the effects of race and poverty on breast
cancer outcomes. J Natl Cancer Inst 94: 471–473
Collaborative Group on Hormonal Factors in Breast Cancer (2002) Breast
cancer and breastfeeding: collaborative reanalysis of individual data
from 47 epidemiological studies in 30 countries, including 50302 women
with breast cancer and 96973 women without the disease. Lancet 360:
187–195
Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K,
Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J,
Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC (2006)
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer
Study. JAMA 295: 2492–2502
Chang S, Parker SL, Pham T, Buzdar AU, Hursting SD (1998) Inflammatory
breast carcinoma incidence and survival: the surveillance, epidemiology,
and end results program of the National Cancer Institute, 1975–1992.
Cancer 82: 2366–2372
Cox D (1972) Regression models and life-tables. J Roy Statist Soc B 1972:
187–220
Dignam JJ, Redmond CK, Fisher B, Costantino JP, Edwards BK (1997)
Prognosis among African-American women and white women with
lymph node negative breast carcinoma: findings from two randomized
clinical trials of the National Surgical Adjuvant Breast and Bowel Project
(NSABP). Cancer 80: 80–90
Eley JW, Hill HA, Chen VW, Austin DF, Wesley MN, Muss HB,
Greenberg RS, Coates RJ, Correa P, Redmond CK, Hunter CP,
Herman AA, Kurman R, Blacklow R, Shapiro S, Edwards BK
(1994) Racial differences in survival from breast cancer. Results of the
National Cancer Institute Black/White Cancer Survival Study. JAMA 272:
947–954
Elledge RM, Clark GM, Chamness GC, Osborne CK (1994) Tumor biologic
factors and breast cancer prognosis among white, Hispanic, and black
women in the United States. J Natl Cancer Inst 86: 705–712
El-Tamer MB, Homel P, Wait RB (1999) Is race a poor prognostic factor in
breast cancer? J Am Coll Surg 189: 41–45
Frank TS, Deffenbaugh AM, Reid JE, Hulick M, Ward BE, Lingenfelter B,
Gumpper KL, Scholl T, Tavtigian SV, Pruss DR, Critchfield GC (2002)
Clinical characteristics of individuals with germline mutations in
BRCA1 and BRCA2: analysis of 10000 individuals. J Clin Oncol 20:
1480–1490
Gukas ID, Jennings BA, Mandong BM, Igun GO, Girling AC,
Manasseh AN, Ugwu BT, Leinster SJ (2005) Clinicopathological features
and molecular markers of breast cancer in Jos, Nigeria. West Afr J Med
24: 209–213
Hershman D, McBride R, Jacobson JS, Lamerato L, Roberts K, Grann VR,
Neugut AI (2005) Racial disparities in treatment and survival among
women with early-stage breast cancer. J Clin Oncol 23: 6639–6646
http://www.statistics.gov.uk/census2001/profiles/commentaries/ethnicity.asp,
2001
Jones BA, Kasl SV, Howe CL, Lachman M, Dubrow R, Curnen MM,
Soler-Vila H, Beeghly A, Duan F, Owens P (2004) African-American/
White differences in breast carcinoma: p53 alterations and other tumor
characteristics. Cancer 101: 1293–1301
Jordan H, Roderick P, Martin D (2004) The Index of Multiple Deprivation
2000 and accessibility effects on health. J Epidemiol Community Health
58: 250–257
Joslyn SA, West MM (2000) Racial differences in breast carcinoma survival.
Cancer 88: 114–123
Nanda R, Schumm LP, Cummings S, Fackenthal JD, Sveen L, Ademuyiwa F,
Cobleigh M, Esserman L, Lindor NM, Neuhausen SL, Olopade OI (2005)
Genetic testing in an ethnically diverse cohort of high-risk women: a
comparative analysis of BRCA1 and BRCA2 mutations in American
families of European and African ancestry. JAMA 294: 1925–1933
Newman LA, Alfonso AE (1997) Age-related differences in breast cancer
stage at diagnosis between black and white patients in an urban
community hospital. Ann Surg Oncol 4: 655–662
Newman LA, Bunner S, Carolin K, Bouwman D, Kosir MA, White M,
Schwartz A (2002) Ethnicity related differences in the survival of young
breast carcinoma patients. Cancer 95: 21–27
Newman LA, Griffith KA, Jatoi I, Simon MS, Crowe JP, Colditz GA (2006)
Meta-analysis of survival in African American and white American
patients with breast cancer: ethnicity compared with socioeconomic
status. J Clin Oncol 24: 1342–1349
Okobia M, Bunker C, Zmuda J, Kammerer C, Vogel V, Uche E, Anyanwu S,
Ezeome E, Ferrell R, Kuller L (2006) Case–control study of risk factors
for breast cancer in Nigerian women. Int J Cancer 119(9): 2179–2185
Olopade OI, Fackenthal JD, Dunston G, Tainsky MA, Collins F, Whitfield-
Broome C (2003) Breast cancer genetics in African Americans. Cancer 97:
236–245
Parra EJ, Marcini A, Akey J, Martinson J, Batzer MA, Cooper R, Forrester T,
Allison DB, Deka R, Ferrell RE, Shriver MD (1998) Estimating African
American admixture proportions by use of population-specific alleles.
Am J Hum Genet 63: 1839–1851
Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA,
Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov
A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO,
Botstein D (2000) Molecular portraits of human breast tumours. Nature
406: 747–752
Quinn JE, Kennedy RD, Mullan PB, Gilmore PM, Carty M, Johnston PG,
Harkin DP (2003) BRCA1 functions as a differential modulator of
chemotherapy-induced apoptosis. Cancer Res 63: 6221–6228
Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M,
Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C,
Rabiul I, Ross JS, Hortobagyi GN, Pusztai L (2005) Breast cancer
molecular subtypes respond differently to preoperative chemotherapy.
Clin Cancer Res 11: 5678–5685
Selaru FM, Yin J, Olaru A, Mori Y, Xu Y, Epstein SH, Sato F, Deacu E,
Wang S, Sterian A, Fulton A, Abraham JM, Shibata D, Baquet C, Stass SA,
Meltzer SJ (2004) An unsupervised approach to identify molecular
phenotypic components influencing breast cancer features. Cancer Res
64: 1584–1588
Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T,
Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC,
Brown PO, Botstein D, Eystein Lønning P, Børresen-Dale AL (2001) Gene
expression patterns of breast carcinomas distinguish tumor subclasses
with clinical implications. Proc Natl Acad Sci USA 98: 10869–10874
Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S,
Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lønning PE, Brown
PO, Børresen-Dale AL, Botstein D (2003) Repeated observation of breast
tumor subtypes in independent gene expression data sets. Proc Natl Acad
Sci USA 100: 8418–8423
Turner N, Tutt A, Ashworth A (2005) Targeting the DNA repair defect of
BRCA tumours. Curr Opin Pharmacol 5: 388–393
van’t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M,
Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ,
Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH (2002)
Gene expression profiling predicts clinical outcome of breast cancer.
Nature 415: 530–536
Vincent-Salomon A, Gruel N, Lucchesi C, MacGrogan G, Dendale R,
Sigal-Zafrani B, Longy M, Raynal V, Pierron G, de Mascarel I, Taris C,
Stoppa-Lyonnet D, Pierga JY, Salmon R, Sastre-Garau X, Fourquet A,
Delattre O, de Cremoux P, Aurias A (2007) Identification of
typical medullary breast carcinoma as a genomic sub-group of basal-
like carcinomas, a heterogeneous new molecular entity. Breast Cancer
Res 9: R24
Breast cancer patterns in British black women
RL Bowen et al
281
British Journal of Cancer (2008) 98(2), 277–281 & 2008 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
s